血清富亮氨酸α-2糖蛋白在评估小肠克罗恩病疾病活动度中的价值  

Value of serum leucine-rich alpha-2 glycoprotein in evaluating the disease activity of small bowel Crohn's disease

作　　者：朱亚龙 黄婧怡 李玥 Zhu Yalong;Huang Jingyi;Li Yue(Department of Gastroenterology,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院、北京协和医学院、北京协和医院消化内科,北京100730

出　　处：《中华炎性肠病杂志（中英文）》2024年第3期238-241,共4页Chinese Journal of Inflammatory Bowel Diseases

基　　金：北京市自然科学基金(7212078);中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-062)。

摘　　要：小肠克罗恩病(CD)起病隐匿,肠狭窄、瘘管等并发症发生风险高,预后不佳。目前临床评估小肠CD疾病活动度的生物标志物仍不理想,缺少无创且能灵敏反映小肠CD活动度的生物标志物。研究发现血清富亮氨酸α-2糖蛋白(LRG)水平与小肠CD的疾病活动度呈正相关。本文综述LRG评估小肠CD的相关研究,并展望其应用前景。Small bowel Crohn's disease(CD)has a hidden onset,with a high risk of complications such as intestinal stenosis and fistulas,and a poor prognosis.Currently,there is still no ideal biomarker for clinical assessment of disease activity in small bowel CD,and there is a lack of non-invasive biomarkers that can sensitively reflect the activity of small bowel CD.Studies have found that the serum level of leucine-rich alpha-2 glycoprotein(LRG)is positively correlated with the disease activity of small bowel CD.This article reviews the relevant research of LRG in evaluating the small bowel CD and looks into its potential application prospects.

关 键 词：小肠克罗恩病 富亮氨酸α-2糖蛋白 生物标志物 疾病活动度 

分 类 号：R574[医药卫生—消化系统]